Skip to content
Peptigraph home

MOTS-c and SLU-PP-332 Together: What Is Known

MOTS-c and SLU-PP-332 taken together: what each one is, how each is regulated, and what is known about combining them.

Medically reviewed by Juan Pablo Frías, MD · · DisclosureUpdated
Mitochondrial-derived peptidePCAC voted 7–5 for 503A (Jul 2026)MOTS-cMitochondrial-derived peptide; human studies found only measured the body's own circulating levels (for example after repeated heat treatment), not administered MOTS-c.[4]GLP-1 & metabolicERR agonist (not a peptide)Not FDA approved · research chemicalSLU-PP-332Experimental ERR agonist (not a peptide) with no human studies; in mice, SLU-PP-332 increased energy expenditure and fatty acid oxidation, mimicking exercise.[12]GLP-1 & metabolic
Interaction notes

Timing, interactions and safety

Evidence for the combination

No studies tested these together (PubMed search: 0 results, 2 Oct 2026).

MOTS-c is not FDA approved, and we have no sourced data on combining it with SLU-PP-332.
Each component

Side by side

Showing 11 of 13 fields where the two differ. Category, Half-life are the same or both unknown.

FieldMOTS-cSLU-PP-332
ClassMitochondrial-derived peptideERR agonist (not a peptide)
Also calledmotsslupp, SLU-PP
FDA statusPCAC voted 7–5 for 503A (Jul 2026)Not FDA approved · research chemical
PCAC vote, Jul 2026PCAC voted 7–5 for the 503A list (Jul 2026); not finalizedNot on the Jul 2026 agenda
WADAProhibited by WADA (S4.4.1)MOTS-c is named in S4.4.1 (metabolic modulators: AMPK activators), prohibited at all times.WADA status unclearSLU-PP-332 is not named. S4.4 lists AMPK activators, PPAR-delta agonists and Rev-erb agonists; SLU-PP-332 is an ERR agonist, which the list does not mention. This is not named on the 2026 list. The catch-all class S0 prohibits any drug with no approval anywhere for human use, so it would be banned if no health authority has approved it, but we have not verified that for this substance.
Anti-doping detection
  • A plasma (blood) test for MOTS-c has been validated to WADA standards.PMID 30394592
None reportedanti-doping literature, as of 2 Oct 2026
Evidence strengthHuman RCT evidence, 4 of 4Strongest: Medicine and science in sports and exercise 2025, PMID 40674654Animal evidence, 2 of 4Strongest: The Journal of pharmacology and experimental therapeutics 2024, PMID 37739806
Human studies we summarised7 human (4 randomized or controlled) of 15 summarised0 human (0 randomized or controlled) of 7 summarised
Typical study dosesNot reported in study abstractsPubMed search, 2 Oct 2026
Vial sizes sold5 mg, 10 mg, 20 mg, 40 mg5 mg
US searches per month60,500 · +437% searches27,100 · −38% searches
Related tools

MOTS-c vs SLU-PP-332

Choosing between the two rather than combining them? The comparison lines them up field by field.

Open the comparison
ComparisonSLU-PP-332 vs MOTS-c

What people search

  • slu pp 332 and mots c20/mo
  • mots c slu pp 332 stack20/mo
  • mots c and slu pp 332 together20/mo
  • slu pp 332 mots c stack10/mo
  • slu pp 332 mots c10/mo
  • slu pp 332 and mots c together10/mo

US monthly searches, Google Keyword Planner, Oct 2026. Shown so you can see which questions this page answers.

Sources

  1. 1FDA gives notice that 12 peptides will be removed from Category 2 (nominations withdrawn)FDA · 2026fda.govAccessed 2 Oct 2026
  2. 2World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
  3. 3Development of a mass spectrometry based detection method for the mitochondrion-derived peptide MOTS-c in plasma samples for doping control purposes.Rapid communications in mass spectrometry : RCM · 2019PMID 30394592Accessed 2 Oct 2026
  4. 4Repeated Heat Stress Modulates the Levels of the Mitokines MOTS-C and FGF21 in Active Men during Calf Muscle Immobilization.Medicine and science in sports and exercise · 2025PMID 40674654Accessed 2 Oct 2026
  5. 5Circulating levels of MOTS-c in patients with breast cancer treated with metformin.Aging · 2022PMID 36490309Accessed 2 Oct 2026
  6. 6Effect of aerobic and resistance exercise on the mitochondrial peptide MOTS-c in Hispanic and Non-Hispanic White breast cancer survivors.Scientific reports · 2021PMID 34413391Accessed 2 Oct 2026
  7. 7PubMed search: ("MOTS-c"[tiab] OR MOTSc[tiab]) (262 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  8. 8PubMed search: ("MOTS-c"[tiab] OR MOTSc[tiab]) AND (humans[mh] OR human[tiab] OR participants[tiab] OR patients[tiab] OR volunteers[tiab]) (179 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  9. 9PubMed search: ("MOTS-c"[tiab] OR MOTSc[tiab]) AND (randomized controlled trial[pt] OR "clinical trial"[pt] OR "meta-analysis"[pt] OR "systematic review"[pt]) (5 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  10. 10PubMed search: ("MOTS-c"[tiab] OR MOTSc[tiab]) AND (mice[tiab] OR mouse[tiab] OR rat[tiab] OR rats[tiab]) AND (injection[tiab] OR treatment[tiab] OR administration[tiab] OR treated[tiab]) (72 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  11. 11PubMed search: ("MOTS-c"[tiab] OR MOTSc[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (3 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  12. 12A Synthetic ERR Agonist Alleviates Metabolic Syndrome.The Journal of pharmacology and experimental therapeutics · 2024PMID 37739806Accessed 2 Oct 2026
  13. 13PubMed search: "SLU-PP-332"[tiab] (10 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  14. 14PubMed search: SLU-PP-332[tiab] OR SLU-PP-915[tiab] OR "ERR agonist"[tiab] AND exercise mimetic[tiab] (5 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  15. 15PubMed search: ("MOTS-c"[tiab] OR MOTSc[tiab]) AND ("SLU-PP-332"[tiab])PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  16. 16Advisory committee backs 6 of 7 peptides for the 503A listNCPA · 2026ncpa.org

Found an error? Report a correction.